{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:23:55Z","timestamp":1792232635220,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.rpth.2025.102950","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:31:42Z","timestamp":1750793502000},"page":"102950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of asundexian on a panel of coagulation assays"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2512-7494","authenticated-orcid":false,"given":"Julie","family":"Vassart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Bangoup","family":"Ndzatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Didembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Morimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Brisbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Jamart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Demeure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Favresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.102950_bib1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib3","first-page":"622","article-title":"Laboratory assessment of the direct oral anticoagulants: who can benefit?","volume":"79","author":"Akpan","year":"2021","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.rpth.2025.102950_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/10742484231202655","article-title":"Evidence-based management of major bleeding in patients receiving direct oral anticoagulants: an updated narrative review on the role of specific reversal agents","volume":"28","author":"Al Aseri","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.rpth.2025.102950_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.102950_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102950_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.102950_bib9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102950_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.102950_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13895","article-title":"Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.rpth.2025.102950_bib12","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.102950_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2024.03.001","article-title":"Asundexian in atrial fibrillation: can pharmacodynamic data explain the failure?","volume":"236","author":"Vassart","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102950_bib14","article-title":"Factor XI inhibition in cardiovascular disease","volume":"134","author":"Carlin","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.rpth.2025.102950_bib16","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1517\/14740338.2015.1049995","article-title":"Dose tailoring of dabigatran etexilate: obvious or excessive?","volume":"14","author":"Douxfils","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.rpth.2025.102950_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory","volume":"43","author":"Siriez","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2025.102950_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.102950_bib18","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.rpth.2025.102950_bib19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib20","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib22","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13318-023-00838-4","article-title":"Metabolism and disposition of the novel oral factor XIa inhibitor asundexian in rats and in humans","volume":"48","author":"Piel","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rpth.2025.102950_bib24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/bcp.15981","article-title":"Pharmacokinetics of asundexian with combined CYP3A and P-gp inhibitors and an inducer: target in vitro and in vivo studies","volume":"90","author":"Kanefendt","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.102950_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep16010016","article-title":"Drug-drug interactions of FXI inhibitors: clinical relevance","volume":"16","author":"Ferri","year":"2024","journal-title":"Hematol Rep"},{"key":"10.1016\/j.rpth.2025.102950_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0036-1597296","article-title":"Laboratory assessment of direct oral anticoagulants","volume":"43","author":"Douxfils","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.102950_bib27","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1111\/jth.15884","article-title":"The myths behind DOAC measurement: analyses of prescribing information from different regulatory bodies and a call for harmonization","volume":"20","author":"Gosselin","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/a-1153-5824","article-title":"Can we measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests?","volume":"40","author":"Reda","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2025.102950_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1160\/th15-05-0415","article-title":"Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide","volume":"115","author":"Douxfils","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib31","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102950_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib33","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1053\/j.jvca.2016.09.002","article-title":"Impact of the direct oral anticoagulants on activated clotting time","volume":"31","author":"Dincq","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.rpth.2025.102950_bib34","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCULATIONAHA.106.638460","article-title":"Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents","volume":"114","author":"Camici","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.102950_bib35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jth.15588","article-title":"Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits","volume":"20","author":"Wong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ijlh.12499","article-title":"In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies","volume":"38","author":"Toulon","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2025.102950_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.12.023","article-title":"Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency","volume":"163","author":"Salloum-Asfar","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102950_bib38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2011.11.016","article-title":"Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents","volume":"129","author":"Gouin-Thibaut","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.102950_bib39","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1055\/a-2359-0987","article-title":"Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points","volume":"8","author":"Gouin-Thibault","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2025.102950_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102860","article-title":"Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Society of Thrombosis and Haemostasis (SFTH)","volume":"9","author":"Godier","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.102950_bib41","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1055\/s-0038-1657785","article-title":"Evaluation of the DOAC-Stop(R) procedure to overcome the effect of DOACs on several thrombophilia screening tests","volume":"2","author":"Favresse","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2025.102950_bib42","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.rpth.2025.103242","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000}},{"DOI":"10.1016\/j.rpth.2025.103242","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925002742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925002742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:16:50Z","timestamp":1773843410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925002742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2475037925002742"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102950","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of asundexian on a panel of coagulation assays","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.102950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102950"}}